Alternative Inhibition Strategy For Treating Acute Promyleocytic Leukemia

The acid form of vitamin A (retinoic acid; RA) is used to treat a type of leukemia known as acute promyleocytic leukemia (APL). It works by binding to its receptors (retinoic acid receptors, RARs) and driving the leukemic cells to mature and die, rather than remain blocked at a highly proliferative immature stage of development. Researchers from the Fred Hutchinson Cancer Research Center in Seattle have now shown that a protein complex known as CaMKII inhibits RAR activity and that CaMKII inhibitors drive leukemic cells to mature and die, thereby identifying a potential alternative treatment for individuals with RA-sensitive APL.

In the study, which appears online in advance of publication in the May print issue of the Journal of Clinical Investigation, Steven Collins and colleagues show that in human myeloid leukemia cell lines the CaMKII CaMKII-gamma interacts with RAR and inhibits its function by phosphorylating RAR-alpha, thereby enhancing the interaction between RAR-alpha and transcriptional corepressors. Furthermore, an inhibitor of CaMKs, KN62, induced myeloid leukemia cell lines to mature, leading the authors to suggest that CaMKII-gamma might provide a new target for the treatment of individuals with RA-sensitive myeloid leukemias.

TITLE: CaMK II regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells

AUTHOR CONTACT:
Steven J. Collins
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

About the Author

srima has written 1902 stories on this site.

Write a Comment

Gravatars are small images that can show your personality. You can get your gravatar for free today!

You must be logged in to post a comment.

Copyright © 2009 Medical News. All rights reserved.
Powered by WordPress.org, Custom Theme and ComFi.com Calling Card Company.
Close